Autoimmunity

Why autoimmunity matters

• It is common and rising. Autoimmune diseases collectively affect an estimated 5 to 8 percent of the population — more than 24 million people in the United States alone — and antinuclear-antibody positivity in the US population rose from about 11 percent to 16 percent between the late 1980s and the 2010s, an increase too fast to be genetic and pointing at environment, diet, and the microbiome.
• It targets the young and the productive. Type 1 diabetes and multiple sclerosis typically begin in childhood or early adulthood; lupus most often strikes women of reproductive age. Unlike cancer or heart disease, autoimmunity front-loads its burden onto decades of life that would otherwise be healthy, making it a leading cause of chronic disability in the young.
• It revealed the rules of self-tolerance. Rare monogenic tolerance failures — APECED from AIRE mutation and IPEX from FOXP3 mutation — mapped the two arms of tolerance in humans. Each single-gene loss produces catastrophic multi-organ autoimmunity, proving that central deletion and regulatory T cells are not redundant luxuries but load-bearing safeguards.
• Checkpoint biology cuts both ways. The CTLA-4 and PD-1 receptors that enforce peripheral tolerance are the same ones cancer exploits to hide. Checkpoint-inhibitor immunotherapy (ipilimumab, nivolumab) unleashes anti-tumor immunity but induces autoimmune-like immune-related adverse events — colitis, thyroiditis, type-1-diabetes-like insulitis — in a large fraction of treated patients, a real-time demonstration that tolerance is an active, drug-tunable process.
• It drives a large fraction of biologic-drug development. TNF inhibitors (adalimumab, infliximab), B-cell depletion (rituximab), IL-6 blockade (tocilizumab), and IL-17/IL-23 blockade have transformed rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Adalimumab was for years the single best-selling drug in the world, grossing over $20 billion at peak — autoimmunity is not only a biological puzzle but one of the largest markets in medicine.
• New cures are emerging from cell therapy. In 2022–2024, CD19-directed CAR T cells — originally built for leukemia — put severe refractory lupus into drug-free remission by deeply depleting autoreactive B cells, and antigen-specific tolerance approaches (tolerogenic vaccines, Treg therapy) are entering trials. Autoimmunity is shifting from lifelong suppression toward the prospect of resetting the immune system.

Common misconceptions

• "A strong immune system prevents autoimmunity." Autoimmunity is not weakness — it is misdirected strength. The same effector machinery that clears infection (cytotoxic T cells, complement-fixing antibodies, inflammatory cytokines) is turned against self. Immunodeficiency and autoimmunity can even coexist, and paradoxically, some immunodeficiencies (like complement C1q deficiency) strongly predispose to lupus because uncleared apoptotic debris becomes autoantigen.
• "Autoantibodies always cause the disease." Sometimes they are the direct agent (anti-acetylcholine-receptor in myasthenia gravis, anti-dsDNA immune complexes in lupus nephritis), but in type 1 diabetes and multiple sclerosis the destruction is largely T-cell-mediated and the autoantibodies are predictive markers, not the executioners. Presence of an autoantibody establishes loss of tolerance; it does not prove the antibody is doing the damage.
• "Autoimmunity comes from an outside toxin or a single bad gene." Except for rare monogenic syndromes, autoimmune disease is polygenic and multifactorial. Even in identical twins, concordance for type 1 diabetes is only about 30 to 50 percent, so genes set the stage but environment — infections, smoking, vitamin D, the gut microbiome, molecular mimicry — pulls the trigger.
• "It is the same as allergy." Allergy (type I hypersensitivity) is an IgE-mediated response to a harmless external antigen. Autoimmunity is a response to a self antigen and is usually mediated by IgG, immune complexes, or T cells (types II, III, and IV hypersensitivity). Both are misdirected immunity, but the target — foreign versus self — is the defining difference.
• "Organ-specific and systemic autoimmunity are one category." They behave very differently. Organ-specific disease (type 1 diabetes, Hashimoto's, MS) concentrates damage on one tissue whose antigen is targeted. Systemic disease (lupus, systemic sclerosis) targets ubiquitous intracellular antigens like DNA and nuclear proteins, so immune complexes deposit throughout the body. The autoantigen's tissue distribution predicts the clinical picture.
• "Once tolerance breaks, the response stays fixed on one antigen." It spreads. Epitope spreading means an initially narrow attack on one part of one protein broadens over time to additional epitopes and additional antigens as tissue damage releases new self-material. This is why autoimmune diseases tend to progress and why early intervention, before spreading, is more effective.

How autoimmunity works

Every day the thymus and bone marrow generate lymphocytes bearing randomly rearranged receptors — the product of V(D)J recombination — so a fraction inevitably recognize self. The immune system's answer is two sequential filters. Central tolerance acts during development. In the thymic medulla, epithelial cells driven by the transcription factor AIRE (autoimmune regulator) ectopically express thousands of tissue-restricted antigens they would never normally make — insulin, thyroglobulin, myelin basic protein — and display them on MHC. A developing T cell whose receptor binds self-peptide-MHC too avidly undergoes negative selection, dying by apoptosis, or is redirected into the regulatory T cell lineage. Self-reactive B cells in the marrow are deleted or edit their receptors. Loss of AIRE causes the human syndrome APECED, with autoimmunity against multiple endocrine organs, proving how much of tolerance is written in the thymus.

Central deletion is imperfect — some self-reactive clones always escape — so peripheral tolerance restrains them in blood and lymph node. Three mechanisms dominate. Regulatory T cells, marked by the transcription factor FOXP3, actively suppress autoreactive cells; loss of FOXP3 causes the fatal IPEX syndrome. Anergy silences a T cell that sees its antigen without the second, costimulatory signal (CD28 engaging B7). And inhibitory checkpoint receptors — CTLA-4 and PD-1 — raise the activation threshold on cells that do engage. When these are intact, an escaped self-reactive T cell that wanders into a tissue meets self-antigen without inflammation, receives no costimulation, and shuts itself off.

Autoimmunity begins when this two-layer system is breached, and it almost always takes several hits. A permissive HLA allele — B27, a DRB1 shared-epitope variant, DQ2/DQ8 — presents a particular self-peptide efficiently or in a form that escaped thymic deletion. Additional risk variants (PTPN22, CTLA4, IL23R, IL2RA) lower activation thresholds. Then an environmental trigger arrives: an infection that supplies molecular mimicry (a microbial peptide resembling self, as streptococcal M protein mimics cardiac myosin in rheumatic fever), or tissue injury that releases sequestered antigens and provides the inflammatory danger signals — via dendritic cells and Toll-like receptors — that a naive self-reactive T cell needs for full activation. Once a self-reactive helper T cell is licensed, it provides help to self-reactive B cells, which mature into plasma cells secreting autoantibodies, and it recruits cytotoxic T cells and macrophages. Damage then feeds forward through epitope spreading: destroyed tissue releases new self-antigens, broadening the attack. Depending on antigen distribution, the result is organ-specific (anti-GAD65 and cytotoxic T cells destroying pancreatic beta cells in type 1 diabetes; anti-myelin attack stripping the axon insulation in MS) or systemic (anti-dsDNA immune complexes depositing in kidney, skin, and joints in lupus).

Central vs peripheral tolerance

Feature	Central tolerance	Peripheral tolerance
Location	Thymus (T cells), bone marrow (B cells)	Blood, lymph nodes, spleen, tissues
Timing	During lymphocyte development	On mature circulating cells
Key mechanism	Negative selection / clonal deletion	Tregs, anergy, checkpoint inhibition
Master genes	AIRE (thymic self-antigen display)	FOXP3 (regulatory T cells)
Checkpoint receptors	—	CTLA-4, PD-1
Human failure syndrome	APECED (AIRE mutation)	IPEX (FOXP3 mutation)
Limitation	Can't display every self-antigen; some clones escape	Requires ongoing active suppression

Four landmark autoimmune diseases

Disease	Target tissue / antigen	Key autoantibodies	Main effector	HLA / genetic risk
Type 1 diabetes	Pancreatic beta cells; insulin, GAD65, IA-2	Anti-insulin, anti-GAD65, anti-IA-2, ZnT8	Cytotoxic T cells (insulitis)	HLA-DR3-DQ2, DR4-DQ8; INS, PTPN22
Systemic lupus (SLE)	Ubiquitous nuclear antigens; dsDNA, Sm	Anti-dsDNA, anti-Sm, anti-nuclear (ANA)	Immune complexes + complement	HLA-DR2/DR3; complement C1q, TLR7
Rheumatoid arthritis	Synovial joints; citrullinated proteins	Anti-CCP, rheumatoid factor (anti-IgG)	Th17/TNF-driven synovitis	HLA-DRB1 shared epitope; PTPN22
Multiple sclerosis	CNS myelin; MBP, MOG	Anti-myelin (marker, less pathogenic)	Th1/Th17 + cytotoxic T cells	HLA-DRB1*15:01; IL7R, EBV trigger

Famous experiments and history

• Ehrlich's horror autotoxicus (~1901). Paul Ehrlich coined the Latin phrase to describe the body's presumed prohibition on attacking itself, and famously doubted that autoimmunity could occur at all. His skepticism became dogma and delayed the field for fifty years — a rare case of a foundational immunologist being spectacularly wrong about a phenomenon he named.
• Witebsky and Rose induce thyroiditis (1956). Ernest Witebsky and his student Noel Rose immunized rabbits with extracts of the animals' own thyroid, added adjuvant, and produced anti-thyroglobulin antibodies and lymphocytic infiltration of the thyroid — deliberately breaking self-tolerance for the first time. This experiment demolished horror autotoxicus and created the experimental model of autoimmune disease.
• Roitt and Doniach identify Hashimoto's autoantibodies (1956). In the same year, Ivan Roitt and Deborah Doniach at the Middlesex Hospital detected circulating anti-thyroglobulin antibodies in patients with Hashimoto's thyroiditis, establishing it as the first human disease proven to be autoimmune and linking the rabbit model directly to human pathology.
• Sakaguchi discovers regulatory T cells (1995). Shimon Sakaguchi showed that a small CD4+ subset expressing the IL-2 receptor alpha chain (CD25) actively suppresses autoimmunity: removing these cells from mice caused spontaneous multi-organ autoimmune disease, and adding them back prevented it. The lineage was later defined by the transcription factor FOXP3, whose mutation causes the human IPEX syndrome — the definitive proof that tolerance is enforced by a dedicated cell population, not merely by deletion.
• The EBV–multiple sclerosis link (Bjornevik et al., 2022). Analyzing serum from more than 10 million US military personnel, Kjetil Bjornevik and colleagues showed that Epstein-Barr virus infection raised the risk of later multiple sclerosis about 32-fold, with essentially no MS occurring in the EBV-negative — the strongest evidence yet that a common virus is a near-necessary trigger, most likely through molecular mimicry between EBV nuclear antigen and the myelin protein GlialCAM.
• The Xist ribonucleoprotein and the female bias (Dou et al., 2024). A Stanford group engineered male mice to express Xist — the long noncoding RNA that females use to silence one X chromosome — and found that the Xist ribonucleoprotein complex is itself autoantigenic, seeding autoantibodies and lupus-like disease. This offered the first concrete molecular reason why autoimmunity is roughly four times more common in women, moving the sex bias from statistic to mechanism.